PubRank

Michael S Saag

Author PubWeight™ 282.63‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antibody neutralization and escape by HIV-1. Nature 2003 21.48
2 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009 19.90
3 Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006 17.93
4 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008 16.54
5 Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002 13.91
6 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006 7.49
7 Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009 7.01
8 Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002 5.56
9 Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009 4.96
10 Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005 4.83
11 Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005 4.68
12 The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS 2009 3.78
13 Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004 3.74
14 Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010 3.72
15 Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006 3.72
16 Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 2004 3.48
17 Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007 3.46
18 Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 2008 3.14
19 The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002 2.89
20 Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr 2013 2.78
21 Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr 2012 2.74
22 Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr 2009 2.58
23 Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. Clin Infect Dis 2011 2.57
24 Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012 2.50
25 Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004 2.42
26 Failure to establish HIV care: characterizing the "no show" phenomenon. Clin Infect Dis 2007 2.37
27 Modeling sequence evolution in acute HIV-1 infection. J Theor Biol 2009 2.32
28 Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008 2.29
29 Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol 2009 2.25
30 Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008 2.21
31 Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008 2.13
32 Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS 2013 2.11
33 Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2006 2.07
34 Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009 2.05
35 Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology 2015 1.99
36 Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002 1.98
37 Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011 1.91
38 Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010 1.84
39 Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses 2008 1.84
40 Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 2010 1.79
41 Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011 1.77
42 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med 2006 1.65
43 Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol 2009 1.63
44 Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 2011 1.57
45 Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care 2010 1.55
46 Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr 2009 1.54
47 Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011 1.52
48 A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003 1.51
49 Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003 1.50
50 Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study. Int J Epidemiol 2012 1.50
51 Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013 1.48
52 Antiretroviral prescribing patterns in treatment-naïve patients in the United States. AIDS Patient Care STDS 2010 1.40
53 Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 2006 1.37
54 Ryan White: an unintentional home builder. AIDS Read 2009 1.36
55 Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010 1.34
56 Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr 2012 1.30
57 Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog 2012 1.28
58 Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr 2012 1.27
59 Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era. Clin Infect Dis 2007 1.26
60 Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008 1.22
61 Which policy to ADAP-T: waiting lists or waiting lines? Clin Infect Dis 2006 1.16
62 Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 2010 1.16
63 Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008 1.15
64 Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic. Clin Infect Dis 2010 1.14
65 CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther 2010 1.13
66 HIV infection and obesity: where did all the wasting go? Antivir Ther 2012 1.13
67 Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol 2012 1.11
68 Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS 2008 1.05
69 Patient reported outcomes in routine care: advancing data capture for HIV cohort research. Clin Infect Dis 2011 1.04
70 Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks. AIDS Res Hum Retroviruses 2010 1.03
71 Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011 1.03
72 Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr 2010 1.02
73 HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis 2014 1.00
74 Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS One 2011 0.99
75 HIV care at a crossroads: the emerging crisis in the US HIV epidemic. MedGenMed 2007 0.99
76 Characteristics of an ambulatory palliative care clinic for HIV-infected patients. J Palliat Med 2013 0.98
77 Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. Clin Infect Dis 2010 0.98
78 Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis 2012 0.98
79 Pain is independently associated with impaired physical function in HIV-infected patients. Pain Med 2013 0.97
80 Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr 2011 0.97
81 When to start antiretroviral therapy: as soon as possible. BMC Med 2013 0.95
82 Enfuvirtide. Expert Opin Investig Drugs 2002 0.95
83 Opt-out testing: who can afford to take care of patients with newly diagnosed HIV infection? Clin Infect Dis 2007 0.95
84 Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clin Infect Dis 2010 0.94
85 Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality. J Gen Intern Med 2011 0.94
86 A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics. PLoS One 2010 0.93
87 HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses 2003 0.93
88 Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr 2010 0.92
89 Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. AIDS Behav 2013 0.92
90 Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings. J Acquir Immune Defic Syndr 2007 0.91
91 Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008 0.91
92 Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing care. Sex Transm Dis 2005 0.90
93 Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic. Clin Infect Dis 2008 0.90
94 Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study. AIDS 2009 0.89
95 Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men. Pharmacogenet Genomics 2011 0.88
96 A conceptual framework for understanding chronic pain in patients with HIV. Pain Pract 2013 0.87
97 HIV now firmly established in the Middle Ages. Clin Infect Dis 2011 0.86
98 Qualitative investigation of a Brief Chronic Pain Screening tool in HIV-infected patients. AIDS Patient Care STDS 2014 0.86
99 Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 2010 0.85
100 Sustained HIV viral suppression following treatment interruption: an observational study. AIDS Res Hum Retroviruses 2006 0.85
101 Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]. Curr Opin HIV AIDS 2009 0.85
102 Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications. Health Serv Res 2011 0.85
103 Impact of a computer-assisted, provider-delivered intervention on sexual risk behaviors in HIV-positive men who have sex with men (MSM) in a primary care setting. AIDS Educ Prev 2013 0.84
104 Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials 2012 0.84
105 Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature. AIDS Res Hum Retroviruses 2005 0.84
106 Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. MedGenMed 2006 0.83
107 Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res Hum Retroviruses 2002 0.83
108 Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes. AIDS Res Hum Retroviruses 2012 0.82
109 Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort. J Acquir Immune Defic Syndr 2014 0.82
110 Physical activity and health outcomes among HIV-infected men who have sex with men: a longitudinal mediational analysis. Ann Behav Med 2013 0.81
111 Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol 2010 0.80
112 The role of palliative care in the current HIV treatment era in developed countries. Top Antivir Med 2013 0.80
113 An Algorithm Approach to Determining Smoking Cessation Treatment for Persons Living With HIV/AIDS: Results of a Pilot Trial. J Acquir Immune Defic Syndr 2015 0.80
114 Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr 2013 0.79
115 Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res 2008 0.79
116 Cigarette Smokers are Less Likely to Have Undetectable Viral Loads: Results From Four HIV Clinics. J Addict Med 2016 0.79
117 Aberrant drug-related behaviors: a qualitative analysis of medical record documentation in patients referred to an HIV/chronic pain clinic. Pain Med 2014 0.79
118 Editorial commentary. Viva no difference! Clin Infect Dis 2012 0.77
119 Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States. AIDS Res Hum Retroviruses 2013 0.77
120 Factors Associated with Missed Psychiatry Visits in an Urban HIV Clinic. AIDS Behav 2015 0.76
121 Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared to the General Population. J Acquir Immune Defic Syndr 2017 0.76
122 Age at cancer diagnosis among persons with AIDS. Ann Intern Med 2011 0.76
123 Decline in locomotor functions over time in HIV-infected patients. AIDS 2014 0.76
124 Short Communication: Viral Suppression Is Associated with Increased Likelihood of Colorectal Cancer Screening Among Persons Living with HIV/AIDS. AIDS Res Hum Retroviruses 2015 0.76
125 Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients. AIDS Res Hum Retroviruses 2012 0.75
126 A Randomized Controlled Trial Protocol to Evaluate the Effectiveness of an Integrated Care Management Approach to Improve Adherence Among HIV-Infected Patients in Routine Clinical Care: Rationale and Design. JMIR Res Protoc 2016 0.75
127 Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. Medicine (Baltimore) 2017 0.75
128 Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. AIDS 2016 0.75
129 The role of toxicity-related regimen changes in the development of antiretroviral resistance. AIDS Res Hum Retroviruses 2011 0.75
130 HIV/AIDS: the only thing constant... J Natl Med Assoc 2009 0.75
131 In Memorium: William Ernest Dismukes 1939-2017. J Infect Dis 2017 0.75
132 Roundtable. Who should be providing HIV care? AIDS Clin Care 2006 0.75
133 Risk factors for atrial fibrillation in a multi-center US clinical cohort of people with HIV infection. AIDS 2022 0.75
134 A plea for justice for jailed medical workers. Science 2006 0.75
135 Ryan White CARE Act reauthorization: we need help. AIDS Read 2006 0.75